Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

InsideArbitrage Potential Deal Alert: Magenta Therapeutics (MGTA) explores strategic alternatives

  • February 5, 2023


StockMagenta Therapeutics, Inc.SymbolMGTA
Date Announced02/02/2023Source Press Release
TypeCompany Seeking Strategic Alternatives

Magenta Therapeutics (MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Magenta has made the determination to halt further development of its programs and conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.



Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.